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Background: Huntington’s Disease (HD) is a progressive neurodegenerative disorder with a single causal mutation
in the Huntingtin (HTT) gene. MicroRNAs (miRNAs) have recently been implicated as epigenetic regulators of
neurological disorders, however, their role in HD pathogenesis is not well defined. Here we study transgenic HD
monkeys (HD monkeys) to examine miRNA dysregulation in a primate model of the disease.
Results: In this report, 11 miRNAs were found to be significantly associated (P value < 0.05) with HD in the frontal
cortex of the HD monkeys. We further focused on one of those candidates, miR-128a, due to the corresponding
disruption in humans and mice with HD as well as its intriguing lists of gene targets. miR-128a was downregulated
in our HD monkey model by the time of birth. We then confirmed that miR-128a was also downregulated in the
brains of pre-symptomatic and post-symptomatic HD patients. Additionally, our studies confirmed a panel of
canonical HD signaling genes regulated by miR-128a, including HTT and Huntingtin Interaction Protein 1 (HIP1).
Conclusion: Our studies found that miR-128a may play a critical role in HD and could be a viable candidate as a
therapeutic or biomarker of the disease.
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Over the past decade, the microRNA (miRNA) class of
noncoding RNAs (ncRNAs) has consistently been impli-
cated in the neurogenesis, neurodegenerative, and syn-
aptic plasticity functions of the central nervous system
(CNS) [1-9]. Modulation of miRNA activity has been as-
sociated with a broad scope of CNS disorders, including
schizophrenia, autism, Fragile X, addiction, Parkinson’s
Disease (PD), Alzheimer’s Disease (AD), Frontotemporal
Dementia (FTD), and Huntington’s Disease (HD)
[10-17]. Indeed, the role of miRNA dysregulation in
neurological diseases has come under increasingly in-
tense study during recent years in the quest for novel
therapeutic strategies [9,18].
HD is characterized by progressive brain atrophy, par-
ticularly in the striatum and hippocampus, with associated* Correspondence: awchan@emory.edu
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Although the causative factor for HD is monogenic and
results from expansion in the polyglutamine (polyQ)
region of the Huntingtin (HTT) gene, there is wide vari-
ability in age of onset, polyQ length, and degree of symp-
toms [20,21]. Published reports indicate that epigenetic
factors, such as ncRNA regulation, work in union with
the genetic anomalies to provoke pathogenic outcomes
in HD [22-28].
MiRNA dysregulation has been reported in HD pa-
tients, transgenic HD mice, and in vitro experimental
models [22-28]. Here we examine the miRNA expression
profile of fetal and newborn frontal cortex from HD
monkeys, with corresponding neuropathological analysis
from a subset of those monkeys. The HD monkeys ex-
amined in this study carry the exon 1 of human HTT
gene with an expanded polyQ tract of 27Q – 122Q
(Additional file 1: Table S1), a range well above the
polyQ repeat of 10-11Q in wild-type (WT) rhesus ma-
caque [29,30]. We identified a significant dysregulation
of 11 miRNAs in the HD monkeys and a correlation ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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way. Interestingly, through bioinformatic analysis and
subsequent in vitro studies, miR-128a was found to
regulate the 3’-untranslated regions (3’ UTRs) of the
HTT and Huntingtin Interacting Protein 1 (HIP1) genes.
Additionally, analysis of previously reported datasets
revealed that miR-128a was also downregulated in
the brain tissue of HD mice and humans [22-25]. We
expand on these datasets to show that miR-128a is
downregulated in a cohort of both pre-symptomatic and
post-symptomatic HD patients.
Overall, we report miRNA dysregulation in the brains
of HD monkeys, with parallel miRNA dysregulation in
human patients. We find that neuronally-enriched miR-
NAs may play a fundamental role in HD pathogenesis.
Additionally, we show that the miRNAs implicated in
HD may regulate a significant network of genes within
the HD canonical signaling pathway, providing a new
paradigm approach for a disease with complex molecu-
lar dysregulation.
Results
Genotyping and mRNA expression analysis of HD
monkeys
Genomic DNA (gDNA) isolated from all the control and
HD monkeys was analyzed by PCR for detection of
the mHTT transgene. The amplification products were
subjected to agarose gel electrophoresis. Amplicons
of ~100 bp were observed in samples from HD monkeys
but not from control monkeys (Figure 1A). These ob-
servations are consistent with the anticipated results,
as the primers amplified the junction between the
vector backbone and the 5’ region of the exon 1 of the
mHTT transgene, which distinguish between the mHTT
transgene and the endogenous wild-type HTT gene (see
Additional file 2: Table S2 for primer sequences).
In addition to confirming the genotype of each HD
monkey, the expression of HTT mRNA in cortical tis-
sues was also measured. All HD monkeys displayed sig-
nificantly higher levels of HTT transcript levels than the
controls, with HD7 displaying the highest expression
(Figure 1B). Primers for the mRNA analysis were not
designed to distinguish between the mutant and wild-
type HTT transcripts, therefore, the relative expression
of mHTT in the HD monkeys was determined by com-
paring with the endogenous transcript levels in the
controls.
Expression of mHTT aggregates in HD monkey frontal
cortex
Immunohistochemistry with mEM48, an antibody that
specifically recognizes mutant HTT (mHTT) with ex-
panded polyQ, revealed a wide distribution of neural
cells with mHTT aggregates in the frontal cortex of theHD monkeys (HD4, HD7 and HD8), but not in the con-
trols (C1 and C3) (Figure 2). Intranuclear inclusions
were found in the nucleus (Figure 2A, arrows) and
neuropil aggregates were formed along neuronal pro-
cesses for HD7 and HD8 (Figure 2A, arrow head).
mHTT aggregates and nuclear inclusion in HD4 were
much less prevalent with no neuropil aggregates.
Consistent with the immunohistochemistry results,
Western blots with mEM48 revealed the presence of
oligomeric mHTT aggregates in the stacking gel for the
frontal cortex of all HD monkeys, with no aggregation
observed in control animals (Figure 2B; stacking gel).
Quantitation by densitometry revealed a significant
increase of mHTT aggregates in the frontal cortex of
HD monkeys compared to control animals (P < 0.05)
(Figure 2C). The number of cells with intranuclear inclu-
sions in HD7 was significantly more than those observed
in HD4 and HD8, which have similar number of cells
with intranuclear inclusions (Figure 2D).
Expression of activated caspase-3 and glial fibrillary acidic
protein (GFAP) in HD monkey frontal cortex
Immunohistochemistry was performed using an anti-
body against the activated form of caspase-3, a signaling
molecule involved in the execution phase of apoptosis.
Immunostaining detected caspase-3 positive cells in the
frontal cortex of HD4, HD7 and HD8; however, signifi-
cantly fewer positive cells were observed in the control
monkey brains (Figure 3A-F). Caspase-3 positive cells
also showed enlarged cell bodies with intense nuclear
staining of caspase-3 (Figure 3E and F). The number of
caspase-3 positive neurons in HD7 and HD8 were
significantly higher than that of the control monkeys
(p < 0.05; Figure 3C). HD4 also exhibited increased num-
bers of caspase-3 positive neurons as compared to the
control animals but was not statistically significant.
GFAP immunostaining revealed increased number of
astrocytic positive cells with intense staining in the
frontal cortex of HD monkeys (Figure 2J-L) when com-
pared to the controls monkeys (Figure 2G-I). Consistent
with the immunohistochemical study, Western blot ana-
lysis revealed significantly increased expression of GFAP
in the frontal cortex of HD7 and HD8 when compared
to the control monkeys. However, GFAP level deter-
mined by western blot was not significantly different be-
tween HD4 and control monkeys (Figure 3I).
miRNA array profiling
496 non-control transcripts (from rhesus macaque) were
log2-transformed and normalized. Average probe inten-
sities were filtered to generate a list of 352 rhesus
miRNA probes with a fluorescence intensity exceeding
threshold levels in at least 10% of the samples. Of the
352 detectable probes, 11 were significantly dysregulated
Figure 1 Genotype and miRNA profiling analysis from HD monkey brains and human miR-128a expression. A) Genomic DNA (gDNA)
was isolated from the frontal cortex of 3 GFP control (C1-C3) and 8 HD monkeys (HD1-HD8). The gDNA was amplified using specific primers for
mHTT and the PCR product was analyzed by gel electrophoresis. B) The fold change of HTT mRNA levels for the HD monkeys compared to the
controls was quantitated by qPCR. C) Cluster diagram for dysregulated miRNAs in HD transgenic cortex. miRNA expression values (Log2
transformed & normalized microarray probe intensities) of the dysregulated microRNAs (P value < 0.05) in the HD and GFP control monkey cortex
were median centered. Green squares represent lower than median levels of gene expression; black squares represent median levels of gene
expression; red squares represent higher than median levels of gene expression. Legend units: 1.0 = differs from median probe intensity by one
log 2 unit (2-fold). D) qPCR validation for the expression of 4 of the 5 miRNAs with significant Ingenuity analysis association to the HD pathway
(miR-940 also showed association with the HD pathway, however, no Taqman assays were commercially available). T-test was used to determine
significant differences between HD and control monkeys (P Value < 0.05 indicated by *). E) Expression of miR-128a was quantitated from control,
pre-symptomatic (HD), and post-symptomatic (HD) human striatum samples. Total RNA was extracted and probed with specific Taqman primers
to miR-128 for qPCR. T-tests were used to determine significant differences compared to the control group (P Value < 0.05 indicated by *).
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t-test using Agilent GeneSpringGX 10.0 with condition
P < 1 (Figure 1C and Additional file 3). Of the 11 miR-
NAs significantly (P < 0.05) correlated with HD patho-
genesis, 9 were downregulated while 2 were upregulated
compared to controls (Figure 1C).
Target analysis of dysregulated miRNAs in HD
pathogenesis
We identified the predicted mRNA targets using
TargetScan for all 11 of the significantly altered miRNAs
in the HD monkeys. The list of predicted mRNA targets
for each miRNA was then analyzed by Ingenuity
Software for pathway associations. Ingenuity analysis
revealed significant pathway associations for all of the 11
miRNAs, including CREB signaling in Neurons, Che-
mokine Signaling, IGF-1 Signaling, and Synaptic Long
Term Depression. Furthermore, when examining for
shared pathways for the 11 miRNAs, we discovered that
3 pathways were associated with 7 of the miRNAs, 12
pathways associated with 6 of the miRNAs, and 13 path-
ways associated with 5 of the miRNAs (Additional file 4:
Table S3). Notably, the HD canonical signaling pathwaywas associated with the mRNA targets for 5 of the 11
miRNAs.
For 4 of the 5 miRNAs with significant target associ-
ation to the HD canonical pathway, we confirmed their
expression by qPCR in the monkey cortical tissues (miR-
940 did not have commercially available Taqman primers
for qPCR) (Figure 1D). For the qPCR verification, we fo-
cused on the monkeys (HD4, HD7, and HD8) that had
corresponding pathology. Quantitation by qPCR re-
vealed a significant downregulation of miR-128a in the
brains of the HD monkeys (Figure 1D), consistent with
our microarray results. Additionally, miR-128a was also
downregulated in the brains of pre-symptomatic and
post-symptomatic HD patients (Figure 1E) when com-
pared to controls (p < 0.05).
miR-128a regulates 3’-UTR activity of genes with known
roles in HD canonical pathway
The HD canonical signaling genes HIP-1, HTT, SP-1,
and GRM5 are all predicted gene targets of miR-128a.
To determine whether miR-128a regulates the 3’-UTRs
of these genes, luciferase reporter assays were developed
and co-transfection assays were performed to examine
Figure 2 Expression of mHTT in monkey frontal cortex. A) Brain sections of HD monkey (rHD4, rHD7 and rHD8) and GFP monkey
(C1 and C3) were immunostained with mEM48. Low magnification (upper panels, 40×) and high magnification (lower panels, 100×) shows
that mHTT forms intranuclear inclusions (arrows) and neuropil aggregates (arrowheads). B) mEM48 immunoblot of frontal cortex showed
high-molecular-mass mutant HTT aggregate (arrow) in the stacking gel. γ- tubulin was used as an internal control. C) Quantification of the mHTT
aggregate in the stacking gel showed the relative level of mHTT aggregates in the frontal cortex. All HD monkeys have significantly higher level
of mHTT aggregate compared to the controls. D) The percentage of mEM48 positive cells with or without intranuclear inclusions was calculated
and compared among HD monkey frontal cortex immunostained with mEM48. HD7 has significantly more nuclei with intranuclear inclusions than
HD4 and HD8. The data was presented as mean ± SE. *P < 0.05.
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Transfection of miR-128a mimic significantly reduced
the 3’-UTR activation of the WT constructs for HIP-1,
HTT, SP-1, and GRM5 in the luciferase reporter assays
(Figure 4). Suppression of HIP-1, HTT, and SP-1 by
miR-128a mimic (55%, 36%, and 30% respectively) was
highly significant compared to the negative control (NC)
(p < 0.0001 by One-way ANOVA followed by Tukey’s
post-hoc multiple comparison). GRM5 3’ UTR was sup-
pressed by the miR-128a mimic with a significance of
p < 0.001. None of the site-specific mutant (MUT) con-
trol reporter constructs for the 4 genes examined were
significantly regulated by the miR-128a mimic.
Discussion
In this study, we examine ncRNA regulation in HD
monkeys and identified 11 significant disease-associated
miRNAs. This is the first study which analyzes miRNA
regulation in a transgenic primate model of a human
disease, with a goal of helping to bridge or expand on
previous results in HD rodents and human patients. The
HD monkeys offer a unique resource to identify patho-
genic ncRNA mechanisms that are either conserved
from lower vertebrates to humans or are primate spe-
cific. For example, miR-451, one of the 11 miRNAs wefound modulated in the HD monkeys, is also upregu-
lated in HD patients [24]. However, miR-451 does not
appear to be disrupted in HD mice models, suggesting
the involvement of this miRNA in disease progression
may be restricted to primates. On the contrary, we
found miR-128a downregulated in the HD monkeys and
human patients, and there are published reports also
showing its corresponding downregulation in at least
2 distinct HD mice models [23]. Additionally, our hu-
man data for miR-128a corresponds with other reported
datasets in HD patients [24]. The miR-128a results,
however, were not previously highlighted in the previous
publications.
Although it is important to identify both primate-
specific and conserved molecular mechanisms in disease,
we focused on miR-128a in this study due to the com-
pelling list of genes it is predicted to target in HD, in-
cluding; SP1, HIP1 as well as HTT itself. Our in vitro
luciferase reporter assays revealed the binding sites for
miR-128a in HIP1, SP1, and HTT are all regulated by
miR-128a compared to stringent site-specific mutant
controls. Although we experimentally examined a subset
of the predicted miR-128a gene targets, there are likely
more genes which miR-128a regulates within the HD
pathway. Furthermore, a few of the other 11 miRNAs we
Figure 3 Neuropathology in HD monkey frontal cortex. A-F) An increased number of caspase-3 positive cells in frontal cortex of HD monkeys
(D-E) was observed when compared with control monkeys (A-B). C) Quantification of caspase-3 positive cells in HD and control monkey frontal
cortex showed significant difference between HD monkeys (HD7 and HD8) and control monkey (C1 or C3). However, no difference was observed
between HD4 and the controls. The data are presented as mean ± SE. *P < 0.05 compared with C1, and #P < 0.05 compared with C3. G-L) An
increased number and intensity of GFAP positive cells was observed in HD monkeys (HD7 and HD8) but not in HD4 (J-L). High magnification
(inserts) showed reactive astrocytes in HD7 and HD8 with strong GFAP staining. Quantification of GFAP expression in the HD monkey frontal
cortex showed significant increase expression of GFAP in HD7 and HD8 but not in HD4. The data were presented as mean ± SE. *P < 0.05
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likely to regulate genes within the HD pathway. A future
point of interest could examine whether a distinct group
of miRNAs work together as a network to govern
the HD genes. MiR-940, one of the 11 HD-associated
miRNAs in the transgenic monkeys, is also predicted totarget HTT. Correspondingly, although we examined
miR-128a regulation of the SP1 transcription factor,
other miRNAS identified in this study also bioinformati-
cally bind to SP1 (such as miR-320, miR-133, and miR-
181). Overall, this report points to a collective miRNA
targeting of HTT or genes which regulate HTT (i.e. SP1,
Figure 4 In-vitro analysis of HD-associated miR-128a gene targets. The regulation of the 3’-UTR activity by miR-128 for (A) HIP-1, (B) HTT,
(C) SP-1, and (D) GRM-5 was evaluated in 293-FT cells. 293-FT cells were co-transfected with 10 nM pre-miR-128a or negative control (NC) as well
as luciferase reporter constructs containing the WT or mutant (MUT) 3’- predicted miR-128a binding site for each of the genes. Relative luciferase
activity data were normalized as a percentage of plasmid-only control levels (100%) for each 3’-UTR construct. One-way ANOVA followed by
Tukey’s post-hoc testing confirmed that miR-128a exposure resulted in significant reduction (p < 0.001) in 3’-UTR activity for each WT construct
(as compared to NC); no significant differences between treatments were detected in MUT constructs.
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miRNAs in the HD monkeys are also predicted to target
the insulin like growth factor −1 gene (IGF1) or its re-
ceptor (IGF1-R), including; miR-128a, miR940, miR-320,
and miR133. It has previously been shown that IGF1 sig-
naling is linked to HD and other neurodegenerative dis-
eases [31-33]. Future studies of these other miRNAs and
their target genes, along with miR-128a, could help de-
velop a more complete understanding of ncRNA regula-
tion in HD.
miR-128a is neuronally-enriched [34,35] and one of
the most abundantly expressed miRNAs in human and
mouse brain [36]. A recent report indicated a principal
role for miR-128a in motor activity and neuronal excit-
ability, and its downregulation can provoke epileptic sei-
zures [36]. HD is partly characterized by deficits in
motor activity, leading to significant impact on associ-
ated movements and possible development of seizures in
patients [37,38]. Tan et al. showed that the seizures in
mice with deficient miR-128a expression can be allevi-
ated with treatment of an anti-convulsant drug [36].
Moreover, the authors showed that the ablation of miR-
128a specifically in the dopamine 1 receptor-expressing
neurons (D1-neurons) leads to juvenile hyperactivity and
seizures [36], consistent with other reports implicating
D1-neurons in the symptoms of HD [39].Several studies have also linked miR-128a with tumor
repression and apoptosis [40,41]. Interestingly, apoptosis
related signaling has consistently been implicated in HD
pathogenesis [42-45]. One possibility is that the polyQ
expansion in HTT of HD patients signals for apoptosis
and neurodegenerative cascades through the regulation
of miR-128a. Indeed, we found caspase-3, a component
of the apoptosis pathway [44,46,47], was dysregulated in
HD monkeys (Figure 2). It has also been reported that
miR-128a is involved in the regulation of neuronal
differentiation and survivability, including through the
targeting of transcription factors and neurotrophins
[48,49]. Overexpressing miR-128a represses the levels
of the neurotrophin-3 receptor (NTRK3) gene [48,49]
and the transcription factor E2F3A [50]. Moreover,
it has also been shown that miR-128a can target genes
involved in neuronal differentiation and viability through
the regulation of nonsense-mediated decay (NMD)
[28,51,52]. NMD is an RNA surveillance pathway which
can provoke the degradation of a subset of RNA
transcripts. It has been suggested that increased expres-
sion of miR-128a can modulate the NMD pathway,
resulting in elevated levels of important neuronal pro-
teins [28,51,52].
Overall, our results suggest that miRNAs, and more
specifically miR-128a, may play a pivotal role in HD
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could provide a viable target for future therapeutics, par-
ticularly when one miRNA, such as miR-128a, regulates
multiple genes within the HD signaling pathway.
Methods
HD monkeys and preparation of brain tissues
Brain tissues were collected from 11 monkeys (HD1-
HD8 and C1-C3) (Additional file 1: Table S1). C2 and
HD5 were miscarried at 3 months of gestation and C1,
C3, HD1, HD2, HD3, HD4, and HD6 were miscarried at
4 months of gestation. HD7 and HD8 were delivered at
full term and euthanized on the first day after birth be-
cause of severe involuntary movement and swallowing
or respiratory difficulty, which was previously reported
as rHD4 and rHD5, respectively [53]. C1 and HD4 were
twins, and HD7 and HD8 were also twins. C1-C3 carried
green fluorescent protein (GFP) transgene, and HD1-
HD8 carried the mHTT transgene (exon 1 driven by hu-
man polyubiquitin promoter with expanded polyQ) and
GFP gene [53]. Brain samples were prepared as soon as
miscarried fetuses were retrieved or immediately after
euthanasia. One hemisphere was post-fixed in 4% para-
formaldehyde (PFA) and processed as described in the
following section while the contralateral hemisphere was
immediately dissected into small pieces (~0.5 cm3)
according to distinct brain regions. The dissected brain
regions were snap frozen in liquid nitrogen and stored
at −80°C until analyzed. Sequence and copy analysis of
all monkeys (Additional file 1: Table S1) was carried out
according to previously published protocols [53].
Immunocytochemistry
Post-mortem brain tissues were fixed in 4% paraformal-
dehyde overnight and then saturated in 30% sucrose
solution at 4°C. The brain was then cryo-sectioned cor-
onally to 50 μm using a cryostat and preserved in cryo-
protectant solution at −20°C. Because most monkeys
were miscarried and their brains were immature and
soft, some of the monkey brains were not adequate for
sectioning and subsequent immunohistochemical stud-
ies. Thus, only sections of frontal cortex from C1, C3,
HD4, HD7 and HD8 were used for neuropathological
study. For DAB immunostaining, sections were incu-
bated with 0.3% hydrogen peroxide for 15 minutes,
blocked for 1 hour at room temperature, and incubated
with primary antibody (mEM48 1:1000, caspase-3
1:1000, or GFAP 1:1000) at 4°C overnight. After thor-
ough wash with DPBS, brain sections were incubated
with avidin–biotin using the Vectastain Elite ABC kit
(Vector Laboratories), and immediately stained with 3,
3’-diaminobezidine (DAB; Vector Laboratories) for 30–
40 seconds until optimal signal was reached. The sec-
tions immunostained with caspase-3 were restained inhematoxylin (Richard-Allan scientific) for nuclear stain-
ing. Brain sections were then mounted on slides and ex-
amined by Olympus BX51 microscope.
Western blotting
Frontal cortex tissues from five individual monkeys (C1,
C3, HD4, HD7 and HD8) were homogenized in RIPA
buffer with protease cocktail inhibitor (Sigma). The tis-
sue lysates were sonicated for 10 seconds and then cen-
trifuged for 4 minutes at 1000 rpm at 4°C to pellet
cellular debris. Protein concentrations were determined
by protein assay. Equal amount (30–40 μg) of protein
extract with loading dye was boiled for 5–10 minutes be-
fore loading into 9% (mEM8 and GFAP) polyacrylamide
gels. After electrophoresis, proteins were transferred
onto PVDF membrane (Bio-Rad) followed by blocking
in 5% skim milk for 30 minutes. The membrane was in-
cubated with the primary antibodies mEM48 (1:50 dilu-
tion) or GFAP (1:1000) overnight at 4°C, followed by the
secondary peroxidase-conjugated antibodies for 1 h. Pro-
tein bands were detected with an Amersham ECL kit
(PerkinElmer). Membrane was then labeled with γ-
tubulin (1:2000) as internal control.
Antibodies
Primary antibodies used in this study are as follows: 1)
mouse monoclonal antibody (mEM48) against the N-
terminal region of human HTT with expanded polyQ
was a gift from Dr. XJ Li lab [54]; 2) rabbit antibody
against the activated form of caspase-3 (cleaved caspase-
3 (Asp 175) antibody) was from Cell Signaling; 3) mouse
anti-Glial Fibrillary Acidic Protein (GFAP) monoclonal
antibody was purchased from Millipore; 4) the mouse
anti-gamma-tubulin antibody was purchased from Sigma.
Secondary antibodies for immunohistochemistry were
biotinylated goat anti-rabbit IgG (caspase-3 immuno-
histochemistry) or biotinylated horse anti-mouse IgG
(mEM48 and GFAP immunohistochemistry) from Vector
Labs (Burlingame, CA). Secondary antibodies for West-
ern blotting were peroxidase-conjugated donkey anti-
rabbit or anti-mouse IgG from Jackson Immunoresearch
Labs.
Qualitative analysis of caspase-3 and mEM48
Immunostained sections were examined using a Leica
DMRB microscope, photographed at a magnification
of 10–100 (camera: Leica DC500; Varshaw Scientific,
Atlanta, GA, USA) and captured with computer software
(SPOT Basic). The percentage of caspase-3 positive neu-
rons was calculated based on number of positive cells
per total nuclei. Five randomly captured images at 40×
magnification were used to determine the number of
caspase-3 positive and total number of nuclei for each
monkey. Brain sections were labeled with mEM48 and
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EM48 (mHTT) positive cells with intranuclear inclu-
sions. Eight randomly captured images at 20× magnifica-
tion were used to determine the number of total
number of EM48 positive cells with intranuclear inclu-
sion for each monkey. For quantitation of protein ex-
pression by densitometry with Western blot, bands were
captured and the intensity of positive bands was quanti-
fied with ChemiDox (BIORAD Inc.). All data are pre-
sented as mean ± standard error of the mean (SEM), and
analyzed by one-way ANOVA using Graphpad Prism
software, and followed by Newman-Keuls method for
comparisons between groups.
mHTT transgene characterization
The monkeys were genotyped and estimated copy num-
ber of the mHTT transgene were obtained following
previous published protocols [53]. Additionally, we de-
tected the mutant transgene by gel electrophoresis after
primer-specific PCR amplification. The genomic DNA
(gDNA) was extracted from frontal cortex tissue using
the Wizard Genomic DNA Purification Kit from Pro-
mega following the manufacturer’s protocol. For gen-
omic amplification of the HTT transgene, 60 ng of
gDNA for the 8 HD transgenics and 3 GFP controls was
analyzed by PCR using SsoFast EvaGreen Supermix from
BioRad at a 60.5°C annealing temperature. Primers were
designed to specifically amplify the junction of the hu-
man polyubiquitin C promoter and 5’ region of the
exon1 of the mHTT transgene (see Additional file 2:
Table S2). qPCR was performed using the CFX96 BioRad
CyclerAll amplified products were analyzed by 1.5%
agarose gel and subsequently sequenced for transgene
verification.
qPCR analysis of HTT mRNA in HD monkeys
Quantitation by qPCR was engaged to compare HTT
mRNA levels between the HD and control monkeys.
Total RNA from the cortical tissue was isolated using
Trizol and subsequently treated with DNase to remove
residual genomic DNA contamination. 200 ng of puri-
fied RNA was reverse-transcribed to cDNA (Applied
Biosystems). To quantitate the mRNA levels of HTT, we
custom designed Taqman assays (ABI) specific for the
gene (see Additional file 2: Table S2). HTT transcript was
amplified from the cDNA by qPCR using the Taqman
assay with 1X final concentration of Taqman Universal
PCR Master Mix (ABI). All data were normalized to 18S
rRNA levels. The integrity of all RNA analyzed in this
study was assessed by both a Bioanalyzer and RNA gel
electrophoresis. All RNA was determined to be intact by
the presence of distinct 28SRNA and 18SRNA ribosomal
bands and a greater intensity of the 28SrRNA compared
to the 18SrRNA (see Additional file 5 for RNA gel).miRNA array profiling
Total RNA was isolated from the frontal cortex of all 3
control and all 8 HD transgenic Rhesus monkeys using
Trizol reagent (Invitrogen) according to manufacturer’s
recommendations. RNA samples were sent to Ocean
Ridge Biosciences for analysis using custom multi-
species microarrays containing 496 probes covering 505
mature miRNAs (rhesus) present in the Sanger 15.0
miRBase database. The microarrays were produced by
Microarrays, Inc. (Huntsville, Alabama) and consisted of
epoxide glass substrates with each probe spotted in trip-
licate. Quality of each total RNA sample was assessed
using UV spectrophotometry and agarose gel electro-
phoresis. Low molecular weight (LMW) RNA (~0-200
nucleotides) was purified from total RNA by size frac-
tionation and 3’-end labeled with Oyster-550 fluorescent
dye using the Flash Tag RNA Labeling Kit (Genisphere
Inc., Hatfield, PA). Labeled LMW RNA samples were
hybridized to the arrays according to conditions recom-
mended in the Flash Tag RNA labeling Kit manual. The
microarrays were scanned on an Axon Genepix 4000B
scanner and data were extracted from images using Gen-
ePix V4.1 software.miRNA qPCR quantitation of in monkey and human brain
Dysregulated miRNAs which had predicted targets with
significant HD pathway association, as determined by In-
genuity Pathways Analysis (p-value < 0.05), were sub-
jected to further validation by qPCR. Taqman miRNA
assays (ABI) were used to quantify levels of the selected
candidates. The assay utilized miRNA-specific primers
for both cDNA synthesis and qPCR, and all reactions
were normalized to RNU48 as a small RNA endogenous
control. Additionally, total RNA was prepared by Trizol-
chloroform extractions from human samples for quanti-
tation of miR-128a by qPCR. Human HD brain tissues
were provided by Emory Alzheimer’s Disease Research
Center and the Emory Neuroscience NINDS Core Facil-
ities (ENNCF) Neuropathology Core Service at Emory
University. The use of human tissues was followed and
compiled with NIH guideline. All miR-128a qPCR values
in the human tissues were normalized to the small RNA
endogenous control, RNU6B.TargetScan and Ingenuity pathway analysis of miRNA
candidates
The predicted mRNA targets for all of the 11 miRNAs
significantly dysregulated with HD by microarray (P
value < 0.05) in our study were identified using the Tar-
getScan prediction program. The predicted mRNA tar-
gets for each were then subjected to pathway analysis
using the Ingenuity software to identify potential associ-
ation with the HD signaling pathway (P value < 0.05).
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3’-UTR sequence information was obtained for the rhesus
genes HIP-1, HTT, SP-1 and GRM5 using TargetScan
(Release 5.2: June 2012), UCSC Genome Browser, and
NCBI databases. Sense and anti-sense oligos spanning the
predicted miR-128a binding sites in each gene’s 3’UTR
were custom ordered (Eurofin Operon) (see Additional
file 2: Table S2 for oligo sequences). Additionally, sense
and anti-sense oligos with point mutations in 4 of the 6
nucleotides of the seed region for the miR-128a binding
sites were generated for use as mutant (MUT) controls.
Sense and anti-sense strands for each site were annealed
and ligated into the pmirGLO Dual-Luciferase miRNA
Target Expression Vector (Promega). Constructs were
transformed into High Efficiency JM109 Competent Cells
(Promega). Annealing, ligation, and transformations were
performed according to manufacturer’s recommendations.
Selected clones were mini-prepped using a QIAGEN
Plasmid mini-prep kit, and inserts/sequences were con-
firmed using restriction digests and sequencing.
HEK-293FT cells were used for 3’UTR Luciferase re-
porter transfections. Lipofectamine 2000 (Invitrogen)
was used to transfect plasmids/miR-128a into 293FT
cells according to manufacturer’s recommendations in
96-well plates (coated with 0.1% gelatin, 14,000 cells/
well). Each well was transfected with 40 ng of plasmid
alone (controls), or in combination with 10 nM pre-
miR-128a (Ambion, catalog AM17100) or Negative Con-
trol #2 (Ambion). Following transfection, cells were
grown for 24 hours at 37ºC and luciferase levels were
quantified using the Dual-Glo Luciferase Assay (Pro-
mega) according to vendor instructions; measurements
were read using a Synergy H4 plate reader (BioTek
Instruments, Inc.). All Firefly luciferase data were nor-
malized to Renilla luciferase levels; experiments were
run in quadruplicate and individual experiments were
replicated at least once.
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